Sorilla Prey

Bordeaux, 33000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Cherry Angiomas in Individuals With Neurofibromatosis Type 1.

Cherry Angiomas in Individuals With Neurofibromatosis Type 1.

Journal: JAMA dermatology

Published: August 19, 2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 12, 2026

Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression.

Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 10, 2026

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Erratum: BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2025

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 27, 2025

Brief Communication: Severe Immuno-Induced Rhinosinusitis With Deafness After Ipilimumab and Nivolumab Combination for Melanoma, and Review of the Literature.

Brief Communication: Severe Immuno-Induced Rhinosinusitis With Deafness After Ipilimumab and Nivolumab Combination for Melanoma, and Review of the Literature.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: June 09, 2025

Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.

Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 15, 2024

Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.

Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study.

Journal: Joint bone spine

Published: March 20, 2024

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.

Journal: RMD open

Published: October 07, 2023

Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas.

Improved survival over time with immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinomas.

Journal: Journal of cancer research and clinical oncology

Published: August 23, 2023

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).

Journal: Journal of neurology

Published: August 06, 2023

Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors.

Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 02, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026